We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
Read MoreHide Full Article
West Pharmaceutical Services (WST - Free Report) is scheduled to release third-quarter 2023 results on Oct 26, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 8.21%. WST’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 12.47%.
Q3 Estimates
Currently, the Zacks Consensus Estimate for revenues is pegged at $746.9 million, indicating an improvement of 8.7% from the year-ago period’s level. The consensus mark for earnings is pinned at $1.86 per share, indicating a deterioration of 8.4% year over year.
Factors to Note
West Pharmaceutical’s Proprietary Products was an important contributor to its top-line growth in the first half of 2023. The segment is likely to have exhibited sustained strength in the second quarter as well.
Apart from this, the company is also expected to have witnessed a margin expansion in the aforementioned segment. This is due to a favorable mix of products sold (stemming from high-value products’ [HVP] demand), production efficiencies and higher sales price.
WST has been witnessing a strong uptake of HVP components, which include Westar, Envision and NovaPure offerings. This trend is likely to have continued in the quarter to be reported.
Although the top line declined during the second quarter, demand growth and a strong order book for 2023 are encouraging. The company’s raised guidance for 2023 earnings and revenues is likely to be reflected in the third-quarter results.
West Pharmaceuticals’ business is exposed to foreign currency exchange rate fluctuations that is likely to have positively impacted the company’s third-quarter performance. However, it expects COVID-related sales to decrease further after declining year over year in the past two quarters.
West Pharmaceutical Services, Inc. Price and Consensus
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here as you will see below.
Earnings ESP: West Pharmaceuticals has an Earnings ESP of -1.23%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
The company’s shares have lost 53.8% year to date. PODD’s earnings beat estimates in the last reported quarter. It has a four-quarter average earnings surprise of 126.94%.
IQVIA (IQV - Free Report) has an Earnings ESP of +0.51% and a Zacks Rank of 3.
The stock has lost 2.9% year to date. IQV’s earnings beat estimates in the last reported quarter. IQVIA has a trailing four-quarter average earnings surprise of 2.26%.
DexCom (DXCM - Free Report) has an Earnings ESP of +7.39% and a Zacks Rank of 3.
The stock has lost 16% year to date. DXCM’s earnings beat estimates in the last reported quarter. DexCom has a four-quarter average earnings surprise of 28.83%.
Image: Shutterstock
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
West Pharmaceutical Services (WST - Free Report) is scheduled to release third-quarter 2023 results on Oct 26, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 8.21%. WST’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 12.47%.
Q3 Estimates
Currently, the Zacks Consensus Estimate for revenues is pegged at $746.9 million, indicating an improvement of 8.7% from the year-ago period’s level. The consensus mark for earnings is pinned at $1.86 per share, indicating a deterioration of 8.4% year over year.
Factors to Note
West Pharmaceutical’s Proprietary Products was an important contributor to its top-line growth in the first half of 2023. The segment is likely to have exhibited sustained strength in the second quarter as well.
Apart from this, the company is also expected to have witnessed a margin expansion in the aforementioned segment. This is due to a favorable mix of products sold (stemming from high-value products’ [HVP] demand), production efficiencies and higher sales price.
WST has been witnessing a strong uptake of HVP components, which include Westar, Envision and NovaPure offerings. This trend is likely to have continued in the quarter to be reported.
Although the top line declined during the second quarter, demand growth and a strong order book for 2023 are encouraging. The company’s raised guidance for 2023 earnings and revenues is likely to be reflected in the third-quarter results.
West Pharmaceuticals’ business is exposed to foreign currency exchange rate fluctuations that is likely to have positively impacted the company’s third-quarter performance. However, it expects COVID-related sales to decrease further after declining year over year in the past two quarters.
West Pharmaceutical Services, Inc. Price and Consensus
West Pharmaceutical Services, Inc. price-consensus-chart | West Pharmaceutical Services, Inc. Quote
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here as you will see below.
Earnings ESP: West Pharmaceuticals has an Earnings ESP of -1.23%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Insulet (PODD - Free Report) has an Earnings ESP of +5.00% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company’s shares have lost 53.8% year to date. PODD’s earnings beat estimates in the last reported quarter. It has a four-quarter average earnings surprise of 126.94%.
IQVIA (IQV - Free Report) has an Earnings ESP of +0.51% and a Zacks Rank of 3.
The stock has lost 2.9% year to date. IQV’s earnings beat estimates in the last reported quarter. IQVIA has a trailing four-quarter average earnings surprise of 2.26%.
DexCom (DXCM - Free Report) has an Earnings ESP of +7.39% and a Zacks Rank of 3.
The stock has lost 16% year to date. DXCM’s earnings beat estimates in the last reported quarter. DexCom has a four-quarter average earnings surprise of 28.83%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.